SLC2A1 and cancer: In this quest, miRNA to GLUT1, GLUT3, and GLUT4 has shown promising antineoplastic potential in prevalent cancers like lung, prostate, breast, colorectal carcinoma, bladder cancer, and pancreatic adenocarcinoma (Lu et al., 2010; Chen et al., 2012; Fei et al., 2012; Chen et al., 2015; Zhao et al., 2017; Pedroza-Torres et al., 2019; Azizi et al., 2021; Shiah et al., 2021).